AI Portfolio Summary
In 2025 Q4, Ally Bridge Group (NY) LLC maintained a portfolio of 33 distinct positions. The most significant new addition to the portfolio was ABIVAX SA, which now represents 9.83% of the total fund value. Conversely, Ally Bridge Group (NY) LLC completely exited their position in SOLENO THERAPEUTICS .
Total Positions
33
Quarter
2025 Q4
Top Holding
REPL (12.2%)
Top 10 Concentration
77.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 33
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
REPL
CALL
REPLIMUNE GROUP...
|
CALL Option | 12.15% | 9.19% |
#1
2
Prev: #3
|
5.1 | -2,400,000 | -66.7% |
P
S
|
1,200,000 | $11,664,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 9.83% | — |
#2
Prev: #—
|
5.9 | 70,000 | no change |
NEW
|
70,000 | $9,439,850 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 8.10% | 12.45% |
#3
2
Prev: #1
|
3.4 | -134,454 | -44.5% |
P
S
|
168,029 | $7,779,743 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPS
CALL
COMPASS PATHWAY...
|
CALL Option | 7.91% | 4.00% |
#4
4
Prev: #8
|
3.2 | -45,700 | -4.0% |
P
S
|
1,100,000 | $7,590,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATAI
ATAI BECKLEY NV
|
Healthcare | 7.30% | 7.37% |
#5
Prev: #5
|
3.0 | -573,900 | -25.1% |
P
S
|
1,713,105 | $7,006,599 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IVA
INVENTIVA SA
|
Healthcare | 7.27% | — |
#6
Prev: #—
|
4.9 | 1,500,000 | no change |
NEW
|
1,500,000 | $6,975,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NERV
MINERVA NEUROSC...
|
Healthcare | 6.93% | — |
#7
Prev: #—
|
4.8 | 1,655,500 | no change |
NEW
|
1,655,500 | $6,655,110 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
PUT
EDGEWISE THERAP...
|
PUT Option | 6.46% | — |
#8
Prev: #—
|
4.6 | 250,000 | no change |
NEW
|
250,000 | $6,203,750 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 6.10% | — |
#9
Prev: #—
|
4.4 | 19,882 | no change |
NEW
|
19,882 | $5,860,021 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 5.04% | — |
#10
Prev: #—
|
4.0 | 195,000 | no change |
NEW
|
195,000 | $4,838,925 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
CALL
UNIQURE NV
|
CALL Option | 4.99% | — |
#11
Prev: #—
|
4.0 | 200,000 | no change |
NEW
|
200,000 | $4,786,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EPRX
EUPRAXIA PHARMA...
|
Healthcare | 3.13% | 3.29% |
#12
Prev: #12
|
1.4 | -517,105 | -56.5% |
P
S
|
397,895 | $3,004,107 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OVID
OVID THERAPEUTI...
|
Healthcare | 3.03% | — |
#13
Prev: #—
|
3.2 | 1,785,000 | no change |
NEW
|
1,785,000 | $2,909,550 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TSHA
CALL
TAYSHA GENE THE...
|
CALL Option | 2.86% | — |
#14
Prev: #—
|
3.1 | 500,000 | no change |
NEW
|
500,000 | $2,750,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 2.62% | 3.78% |
#15
6
Prev: #9
|
1.3 | -1,440,980 | -75.9% |
P
S
|
457,132 | $2,514,226 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLDB
SOLID BIOSCIENC...
|
Healthcare | 2.43% | 2.06% |
#16
2
Prev: #18
|
1.0 | -135,557 | -24.7% |
P
S
|
413,625 | $2,332,845 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WHWK
WHITEHAWK THERA...
|
Healthcare | 2.06% | 0.95% |
#17
5
Prev: #22
|
0.8 | no change | no change |
P
S
|
817,939 | $1,979,412 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PMN
PROMIS NEUROSCI...
|
Healthcare | 1.77% | 1.61% |
#18
1
Prev: #19
|
1.0 | -5,984,158 | -96.0% |
P
S
|
249,339 | $1,701,739 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
CALL
SOLENO THERAPEU...
|
CALL Option | 0.00% | 10.29% |
Sold All 😨
(Was: #2) |
0.3 | -250,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MDGL
MADRIGAL PHARMA...
|
Healthcare | 0.00% | 9.12% |
Sold All 😨
(Was: #4) |
0.3 | -32,662 | -100.0% |
CLOSED
|
— | $— | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 0.00% | 6.18% |
Sold All 😨
(Was: #6) |
0.3 | -51,080 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LENZ
LENZ THERAPEUTI...
|
Healthcare | 0.00% | 4.97% |
Sold All 😨
(Was: #7) |
0.3 | -175,363 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 0.00% | 3.62% |
Sold All 😨
(Was: #10) |
0.3 | -437,391 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 0.00% | 3.58% |
Sold All 😨
(Was: #11) |
0.3 | -1,026,382 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
CALL
PRAXIS PRECISIO...
|
CALL Option | 0.00% | 3.23% |
Sold All 😨
(Was: #13) |
0.3 | -100,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNPR
MONOPAR THERAPE...
|
Healthcare | 0.00% | 3.21% |
Sold All 😨
(Was: #14) |
0.3 | -64,455 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARQT
ARCUTIS BIOTHER...
|
Healthcare | 0.00% | 2.68% |
Sold All 😨
(Was: #15) |
0.3 | -233,220 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNMD
MIND MEDICINE M...
|
Healthcare | 0.00% | 2.60% |
Sold All 😨
(Was: #16) |
0.3 | -361,444 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 0.00% | 2.56% |
Sold All 😨
(Was: #17) |
0.3 | -70,778 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.00% | 1.38% |
Sold All 😨
(Was: #20) |
0.3 | -178,100 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TECX
TECTONIC THERAP...
|
Healthcare | 0.00% | 1.32% |
Sold All 😨
(Was: #21) |
0.3 | -138,595 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLTX
CALL
MOONLAKE IMMUNO...
|
CALL Option | 0.00% | 0.30% |
Sold All 😨
(Was: #23) |
0.3 | -69,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATYR
CALL
ATYR PHARMA INC
|
CALL Option | 0.00% | 0.26% |
Sold All 😨
(Was: #24) |
0.3 | -600,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 33 holdings